The FDA Panel unanimously recommends Moderna Covid booster shots for at-risk adults

The Food and Drug Administration’s key advisory board unanimously recommended giving booster shots of Moderna’s Covid-19 vaccine to people over the age of 65 and other vulnerable Americans on Thursday. Those who first received the vaccine.

A non-binding decision by the FDA’s Vaccine and Related Biopharmaceutical Advisory Board provides Moderna guidelines in line with the third inoculation of Pfizer and BioNTech vaccines. In less than a month, these shots will be given to a variety of Americans, including those who work or live in high-risk environments such as the elderly, adults with underlying illness, health and grocery workers, etc. Allowed.

Agencies do not always follow the advice of the Commission, but they often do. The FDA’s final decision on the Moderna booster may be made within a few days. The CDC Vaccine Advisory Board is then expected to vote on the FDA’s proposal next week. If it recommends approval and the CDC approves it, booster shots can be started immediately against eligible Americans who completed immunization at least 6 months ago.

Booster shots have been controversial for scientists inside and outside the government. In particular, many people in the United States and other parts of the world have never been vaccinated. The World Health Organization is urging wealthy countries to postpone the distribution of boosters, and some scientists say they are not convinced that most Americans need boosters now.

When the FDA committee met last month, they rejected the proposal to distribute booster shots of Pfizer and BioNTech vaccines to the general public. Some members of the committee at the time were concerned that there was not enough data to make recommendations, while others argued that third shots should be limited to specific groups. ..

After a unanimous vote in Moderna on Thursday, committee member Dr. Patrick Moore said the data submitted by the company for booster approval was “not well explained” and “intestinal He added that he voted more for “sense.”

“The data itself isn’t strong, but it’s certainly moving in favor of this vote,” he said.

The Biden administration will ensure long-term and lasting protection against serious illness, hospitalization and death as fast-moving delta mutants continue to spread by giving additional doses to the U.S. population. I want

Dr. Peter Marks, FDA’s top vaccine regulator, addressed the Commission Thursday before the vote, encouraging the Expert Committee to “all different perspectives” on “complex and evolving” data. He said he was.

“But as we progress, we focus on science related to the application under consideration today, rather than operational issues related to booster campaigns on issues related to global vaccine equity. I want you to do your best to do it, “he added.

Moderna submitted a booster dose approval to the FDA on September 1st. The company said the results were based on clinical trials of about 170 adults, less than 318 studied for Pfizer boosters. Moderna said the third shot at half the dose (50 micrograms) used for the first two jabs was safe and produced a strong immune response.

The company’s head of infectious disease research, Dr. Jacqueline Miller, said in a presentation Thursday that he would send a letter to healthcare providers explaining the difference in the third dose, with approval.

The side effects of Moderna’s booster were similar to those experienced after the second dose, the company wrote in a document released by the FDA on Tuesday. Most side effects were less severe, and Moderna did not report rare cases of cardiac inflammatory conditions, myocarditis, or pericarditis in study participants until 29 days after receiving booster immunization.

Before recommending the third shot, the panel listened to multiple presentations, including a presentation from Israeli health authorities who began providing boosters to the population ahead of many other countries. The country mainly used Pfizer’s vaccine, but was given some moderna boosters.

Israel has launched 3.7 million third shots since launching its booster campaign in late July, with about one-third of the additional shots aimed at people over the age of 60. I told the panel.

She provided data suggesting that people with booster immunity are less likely to become infected with Covid or become seriously ill. She said authorities have so far identified 17 cases of myocarditis or pericarditis after the third dose.

“Given all the Israeli data to date, I think the booster dose has helped alleviate Israeli infections and severe cases,” she said.

This is a developing story. Please check for updates.

The FDA Panel unanimously recommends Moderna Covid booster shots for at-risk adults

Source link The FDA Panel unanimously recommends Moderna Covid booster shots for at-risk adults

Back to top button